TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02416336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinella Intraoperative imaging protocol
Description: There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed.
Study: NCT04226599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolve AVF
Description: Subjects in the test group will be treated with peripheral scoring drug balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Armada 35
Description: Subjects in the test group will be treated with plain balloon catheter.
Study: NCT04381364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide Inhalation Aerosol
Description: Ciclesonide 320 µg twice daily for 14 days.
Study: NCT02000440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
Study: NCT01967940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to match TAF administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg STR administered orally once daily with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Current failing ARV regimen
Description: Participants will continue taking their current ARV regimen as prescribed in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Current failing ARV regimen
Description: Participants will continue taking their current ARV regimen as prescribed in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Current failing ARV regimen
Description: Participants will continue taking their current ARV regimen as prescribed in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: 300 mg tablet administered orally once daily.
Study: NCT03461835

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk classification of PUL by M4
Description: High or low risk of being an ectopic pregnancy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk classification of PUL by M4
Description: High or low risk of being an ectopic pregnancy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk classification of PUL by NICE
Description: High or low risk of being an ectopic pregnancy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk classification of PUL by NICE
Description: High or low risk of being an ectopic pregnancy
Study: NCT02912676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine (oral)
Description: Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
Study: NCT03709420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to match active drug
Study: NCT01550003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP)
Description: CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CZP)
Description: CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
Study: NCT03469557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Study: NCT02425293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: asthma patient education
Study: NCT03607890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
Study: NCT03675997

Intervention type: OTHER
Intervention: HAD (Hospital Anxiety and Depression) scale
Description: HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
Study: NCT04351581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEi/ARB
Description: Discontinuation of ACEi/ARB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of ACEi/ARB
Description: Discontinuation of ACEi/ARB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of ACEi/ARB
Description: Continuation of ACEi/ARB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of ACEi/ARB
Description: Continuation of ACEi/ARB
Study: NCT02894346

Intervention type: OTHER
Intervention: Teachers
Description: Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
Study: NCT00347022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenetix
Description: 300 mg of iodine/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visipaque
Description: 270 mg of iodine/ml
Study: NCT03953352

Intervention type: OTHER
Group type: OTHER
Intervention: Helical intensity-modulated radiotherapy (IMRT)
Description: Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
Study: NCT00131079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Programme for Physical Activity Promotion
Description: General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
Study: NCT04181658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real tDCS and Physical Therapy
Description: The participant will receive 20-minute sessions of real tDCS before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation and Physical Therapy
Description: The participant will receive 20-minute sessions of sham stimulation before each physical therapy visit for up to 10 combined sessions, over approximately 6 weeks.
Study: NCT03371667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103.
Study: NCT03709420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOR-6219
Description: FOR-6219 capsule
Study: NCT04934540

Intervention type: PROCEDURE
Intervention: En bloc resection of bladder tumour
Description: En bloc resection of bladder tumour (ERBT) is a novel surgical technique in which the bladder tumour is resected in one piece
Study: NCT00740038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management training
Description: Self-administered stress management training comprising 10 minute introduction by staff, \& provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined stress management and exercise training
Description: Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
Study: NCT01538329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: 200mg / day once daily in the morning and at noon - oral administration -
Study: NCT01798771

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interventional arm
Description: 5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control arm
Description: 5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
Study: NCT04046120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel-free bandage
Description: The bandage is made by leaving the heel uncovered.
Study: NCT03891407

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-Testing Education and Promotion
Description: Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
Study: NCT06380621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally Extra Peritoneal repair (TEP) repair
Description: TEP repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally Extra Peritoneal repair (TEP) repair
Description: TEP repair
Study: NCT02015260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Varying doses of sodium nitrite and citric acid co-applied to warts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Varying doses of sodium nitrite and citric acid co-applied to warts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical NO
Description: Varying doses of sodium nitrite and citric acid co-applied to warts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01475760

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum (20mg chitosan)
Description: All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: K2CG chewing gum (60mg chitosan)
Description: Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42
Study: NCT03406312

Intervention type: DIAGNOSTIC_TEST
Intervention: Post Prandial Hypoglycemia test
Description: three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring

Intervention type: DIAGNOSTIC_TEST
Intervention: Post Prandial Hypoglycemia test
Description: three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
Study: NCT01654302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synera
Description: 70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive patch
Description: placebo patch applied once for 12 hours
Study: NCT01970293

Intervention type: OTHER
Group type: OTHER
Intervention: Introduction to AA volunteer
Description: In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
Study: NCT01538329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 200mg / day once daily in the morning and at noon - oral administration -
Study: NCT03975595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Intervention A
Description: This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Intervention B
Description: This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
Study: NCT01958970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PINTA 745
Description: PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Study: NCT02617849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6, every 3 weeks x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, every 3 weeks x 4
Study: NCT01315951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Petroleum Jelly
Description: Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
Study: NCT02618031

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Treatment (EVT)
Description: EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT)
Description: EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.